The αvβ6 integrin as a novel molecular target for colorectal cancer

Future Oncology

Volumn 1, Issue 6, 2005, Pages 821-828

  Bates, Richard C ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

cetuximab; cilengitide; colorectal carcinoma; epithelialmesenchymal transition; integrins; metastasis; vitaxin

Indexed keywords

ALPHAVBETA6 INTEGRIN; INTEGRIN; TUMOR ANTIGEN;

CANCER INVASION; COLORECTAL TUMOR; EPITHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; MESODERM; METABOLISM; PATHOLOGY; REVIEW;

ANTIGENS, NEOPLASM; COLORECTAL NEOPLASMS; EPITHELIAL CELLS; EXTRACELLULAR MATRIX; HUMANS; INTEGRINS; MESODERM; NEOPLASM INVASIVENESS;

EID: 34250681645     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.1.6.821     Document Type: Review

References (52)

1. Markowitz SD, Dawson DM, Willis J, Willson JKV: Focus on colon cancer. Cancer Cell 1(3), 233-236 (2002).
2. McDermott U, Longley DB, Johnston PG: Molecular and biochemical markers in colorectal cancer. Ann. Oncol. 13, 235-245 (2002).
3. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA Cancer J. Clin. 51(1), 15-36 (2001).
4. Goss KH, Groden J: Biology of the adenomatous polyposis coli tumor suppressor. J. Clin. Oncol. 18(9), 1967-1979 (2000).
5. Markowitz S: TGF-a receptors and DNA repair genes, coupled targets in a pathway of human colon carcinogenesis. Biochim. Biophys. Acta 1470(1), M13-M20 (2000).
6. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61(5), 759-767 (1990).
7. Cohen SJ, Cohen RB, Meropol NJ: Targeting signal transduction pathways in colorectal cancer - more than skin deep. J. Clin. Oncol. 23(23), 5374-5385 (2005).
8. Savagner P: Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. BioEssays 23(10), 912-923 (2001).
9. Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr. Opin. Cell. Biol. 15(6), 740-746 (2003).
10. Arias AM. Epithelial mesenchymal interactions in cancer and development. Cell 105(4), 425-431 (2001).
11. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100(1), 57-70 (2000).
12. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nature Rev. Cancer 2(6), 442-454 (2002).
13. Lehmann K, Janda E, Pierreux CE et al.: Raf induces TGFa production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev. 14(20), 2610-2622 (2000).
14. Bhowmick NA, Ghiassi M, Bakin A et al.: Transforming growth factor-a1 mediates epithelial to mesenchymal transdifferentiation through a Rho-Adependent mechanism. Mol. Biol. Cell 12(1), 27-36 (2001).
15. Janda E, Lehmann K, Killisch I et al.: Ras and TGFa cooperatively regulate epithelial cell plasticity and metastasis: dissection of ras signaling pathways. J. Cell Biol. 156(2), 299-314 (2002).
16. Wakefield LM, Roberts AB: TGF-a signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Develop. 12(1), 22-29 (2002).
17. Oft M, Heider KH, Berg H: TGF-a signaling is necessary for carcinoma cell invasiveness and metastasis. Curr. Biol. 8(23), 1243-1252 (1998).
18. Watanabe T, Wu TT, Catalano PJ et al.: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 344(16), 1196-1206 (2001).
19. Hynes RO: Integrins: bi-directional allosteric signaling machines. Cell 110(6), 673-687 (2002).
20. Hwang R, Varner J: The role of integrins in tumor angiogenesis. Hematol. Oncol. Clin. N. Am. 18(5), 991-1006 (2004).
21. Gasparini G, Brooks PC, Biganzoli E et al.: Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin. Cancer Res. 4(11), 2625-2634 (1998).
22. Vonlaufen A, Wiedle G, Borisch B, Birrer S, Luder P, Imhof B: Integrin ava3 expression in colon carcinoma correlates with survival. Mod. Pathol. 14(11), 1126-1132 (2001).
23. Hynes RO: A reevaluation of integrins as regulators of angiogenesis. Nature Med. 8(9), 918-921 (2002).
24. Gotzmann J, Mikula M, Eger A et al.: Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutation Res. 566(1), 9-20 (2004).
25. Bates RC, Mercurio AM: Tumor necrosis factor-a stimulates the epithelial to mesenchymal transition of human colonic organoids. Mol. Biol. Cell 14(5), 1790-1800 (2003).
26. Bates RC, Bellovin DI, Brown C et al.: Transcriptional activation of integrin a6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J. Clin. Invest. 115(2), 339-347 (2005).
27. Breuss JM, Gillett N, Lu L, Sheppard D, Pytela R: Restricted distribution of integrin a6 mRNA in primate epithelial tissues. J. Histochem. Cytochem. 41(10), 1521-1527 (1993).
28. Breuss JM, Gallo J, DeLisser HM et al.: Expression of the a6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J. Cell Sci. 108(Pt6), 2241-2251 (1995).
29. Zbar AP: The immunology of colorectal cancer. Surg. Oncol. 13( 2-3), 45-53 (2004).
30. Smythe WR, Lebel E, Bavaria JE, Kaiser LR, Albelda SM: Integrin expression in nonsmall cell carcinoma of the lung. Cancer Metastasis Rev. 14(3), 229-239 (1995).
31. Arihiro K, Kaneko M, Fujii S, Inai K, Yokosaki Y: Significance of alpha 9 beta 1 and alpha v beta 6 integrin expression in breast carcinoma. Breast Cancer 7(1), 19-26 (2000).
32. Hamidi S, Salo T, Kainulainen T, Epstein J, Lerner K, Larjava H: Expression of ava6 integrin in oral leukoplakia. Br. J. Cancer 82(8), 1433-1440 (2000).
33. Regezi JA, Ramos DM, Pytela R, Dekker, NP, Jordan RCK: Tenascin and a6 integrin are overexpressed in floor of mouth in situ carcinomas and invasive squamous cell carcinomas. Oral Oncol. 38(4), 332-336 (2002).
34. Mogi S, Dang D, Van Waes C, Ellis D, Atakilit A, Ramos DM: The expression of integrin ava6 promotes the epithelial cell morphology and suppresses invasive behavior in transformed oral keratinocytes. AntiCancer Res. 25(2A), 751-756 (2005).
35. Thomas GJ, Lewis MP, Marshall JF, Speight PM: ava6 integrin promotes invasion of squamous carcinoma cells through upregulation of matrix metalloproteinase-9. Int. J. Cancer 92(5), 641-650 (2001).
36. Ramos DM, But M, Regezi J et al.: Expression of integrin a6 enhances invasive behavior in oral squamous cell carcinoma. Matrix Biol. 21(3), 297-307 (2002).
37. Thomas GJ, Lewis MP, Whawell SA: Expression of the ava6 integrin promotes migration and invasion in squamous carcinoma cells. J. Invest. Dermatol. 117(1), 67-73 (2001).
38. Janes SM, Watt FM: Switch from ava5 to ava6 integrin expression protects squamous cell carcinomas from anoikis. J. Cell Biol. 166(3), 419-431 (2004).
39. Bates RC: Gastrointestinal matrix, organization and significance. In:Encyclopedia of Gastroenterology. Johnson LR (Ed.), Elsevier Science, San Diego, CA, USA, 219-223 (2003).
40. Liotta L, Kohn EC: The microenvironment of the tumor-host interface. Nature 411(6835), 375-379 (2001).
41. Tuxhorn JA, Ayala GE, Rowley DR: Reactive stroma in prostate cancer progression. J. Urol. 166(6), 2472-2483 (2001).
42. Munger JS, Huang X, Kawakatsu H et al.: The integrin ava6 binds and activates latent TGFa1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96(3), 319-328 (1999).
43. Weinreb PH, Simon KJ, Rayhorn P et al.: Function-blocking integrin ava6 monoclonal antibodies. Distinct ligandmimetic and non-ligand-mimetic classes. J. Biol. Chem. 279(17), 17875-17887 (2004).
44. Ellis LM, Hoff PM: Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer. J. Clin. Oncol. 22(7), 1177-1179 (2004).
45. Tucker GC: Alpha v integrin inhibitors and cancer therapy. Curr. Opin. Investig. Drugs 4(9), 722-731 (2003).
46. Gutheil JC, Campbell TN, Pierce PR et al.: Targeted anti-angiogenic therapy for cancer using vitaxin: a humanized monoclonal antibody to the integrin ava3. Clin. Cancer Res. 6(8), 3056-3061 (2000).
47. Posey JA, Khazaeli MB, DelGrosso A et al.: A pilot trial of vitaxin, a humanized antivitronectin receptor (anti ava3) antibody in patients with metastatic cancer. Cancer Biother. Radiopharm. 16(2), 125-132 (2001).
48. Eskens FA, Dumez H, Hoekstra R et al.: Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins ava3 and ava5 in patients with advanced solid tumors. Eur. J. Cancer 39(7), 917-926 (2003).
49. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL: Cilengitide targeting of ava3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 62(15), 4263-4272 (2002).
50. Stoeltzing O, Liu W, Reinmuth N et al.: Inhibition of integrin a5a1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int. J. Cancer 104(4), 496-503 (2003).
51. Shannon KE, Keene JL, Settle SL et al.: Antimetastatic properties of RGDpeptidomimetic agents S137 and S247. Clin. Exp. Metas. 21(2), 129-138 (2004).
52. Reinmuth N, Liu W, Ahmad SA et al.: ava3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res. 63(9), 2079-2087 (2003).